Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;2(1):21-28.
doi: 10.3892/ol.2010.199. Epub 2010 Oct 27.

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

Itaru Chiba  1 , Kazuhiko Ogawa, Takamitsu Morioka, Hideaki Shimoji, Nao Sunagawa, Shiro Iraha, Tadashi Nishimaki, Naomi Yoshimi, Sadayuki Murayama
Affiliations

Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy

Itaru Chiba et al. Oncol Lett. 2011 Jan.

Abstract

This study aimed to investigate whether glucose transporter-1 (GLUT-1) expression in a pretreatment esophageal cancer biopsy was predictive of clinical outcomes in patients with esophageal cancer undergoing concurrent chemoradiotherapy (CRT). A total of 25 patients with esophageal cancer treated with concurrent CRT were reviewed. Radiotherapy was administered up to total doses of 40-66.6 Gy (median 66.6 Gy) with a single fraction of 1.8-2 Gy. Regarding chemotherapy, cisplatin (80 mg/m(2) on day 1) and 5-fluorouracil (800 mg/m(2) on days 2-6) were used concurrently with radiotherapy, every 3-4 weeks for a total of 1-2 courses. Tissue samples from esophageal carcinoma were obtained from the 25 patients by biopsy prior to concurrent CRT, and a semiquantitative analysis of GLUT-1 expression was performed using immunohistochemical staining. High GLUT-1 expression was observed in 7 of 25 (28%) patients, and GLUT-1 expression was significantly correlated with clinical T stage (p=0.0454), clinical N stage (p=0.0324) and initial response to CRT (p=0.0185). Patients with a high GLUT-1 expression had significantly poorer local control (LC) (5-year LC 28.6%) than those with a low expression (5-year LC 73.4%, p<005). Multivariate analysis revealed that GLUT-1 and the number of chemotherapy courses were independent prognostic factors for LC. Patients with a high GLUT-1 expression had significantly lower recurrence-free survival (RFS) compared to those with a low GLUT-1 expression (p=0.0405). Multivariate analysis revealed that GLUT-1, the number of chemotherapy courses and clinical M stage were independent prognostic factors for RFS. GLUT-1 expression was significantly correlated with clinical T stage, clinical N stage and initial response to concurrent CRT, and was predictive of LC and RFS for patients with esophageal cancer treated with concurrent CRT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative example of GLUT-1 expression in esophageal carcinoma. Immunohistochemical staining with anti-GLUT-1 antibody in esophageal carcinoma cells. (A) High and (B) low GLUT-1 expression.
Figure 1
Figure 1
Representative example of GLUT-1 expression in esophageal carcinoma. Immunohistochemical staining with anti-GLUT-1 antibody in esophageal carcinoma cells. (A) High and (B) low GLUT-1 expression.
Figure 2
Figure 2
Local control curves according to the GLUT-1 expression in esophageal carcinoma patients treated with concurrent chemoradiotherapy.
Figure 3
Figure 3
Disease-free survival curves according to the GLUT-1 expression in esophageal carcinoma patients treated with concurrent chemoradiotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Roth JA, Putnum JB, Jr, Rich TA, Forastiere AA. Cancer of the esophagus. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles And Practice Of Oncology. 5th edition. Lippincott-Raven; PA: 1997. pp. 980–1021.
    1. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg. 1980;67:381–390. - PubMed
    1. Earlam R, Cunha-Melo JR. Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg. 1980;67:457–461. - PubMed
    1. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623–1627. - PubMed
    1. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–1174. - PubMed